Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers

X
Trial Profile

Double-blind, placebo-controlled, dose-escalating phase 1 trial of LCB10 0200 (GT-1) in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LCB10-0200 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions
  • Most Recent Events

    • 30 May 2018 According to a Geom Therapeutics media release, this trial is expected to begin in 2H of 2018.
    • 30 May 2018 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2018.
    • 27 Sep 2017 According to a Geom Therapeutics media release, the company is planning to initiate Phase 1 studies in 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top